(427) Apatinib-loaded polymeric micelles for ophthalmic delivery to the posterior segment

Introduction: Apatinib, the VEGFR-2 inhibitor, has shown promising efficacy in treating age-related macular degeneration and diabetic retinopathy, both of which are associated with abnormal angiogenesis. Current intravitreal injection (IVI) methods for anti-VEGF agents pose risks of adverse effects and low patient compliance. This study proposes a non-invasive alternative in the form of Apatinib-loaded polymeric micelle (PM) eye drops for posterior segment ocular delivery to improve therapeutic outcomes and patient adherence.